Baby's hand holding its mother's finger

Newsroom

Latest News

News

Sera Prognostics Completes Initial Readout of TREETOP Study Confirming Performance of PreTRM® Test Risk Prediction

Aug. 5, 2019 -Sera announced an initial readout of clinical data from its prospective real-time study, TREETOP, which is designed to assess the performance of the PreTRM® Test for the prediction of prematurity risk in a completely independent large cohort of pregnant women across the U.S.
News

Sera Prognostics Receives New York State Approval for PreTRM® Testing

Dec. 12, 2018 — Sera Prognostics, The Pregnancy Company(™), announced that the New York State Department of Health has issued a clinical laboratory permit for Sera to perform PreTRM® testing for pregnant women in the state of New York. The lab approval was based on the results of an on-site inspection and rigorous evaluation process. With this approval, Sera can now commercialize the PreTRM® test in New York, a very important health care market.
News

Sera Prognostics Completes Enrollment of Large, Multicenter, Prospective Clinical Study of PreTRM® Test

Nov. 27, 2018 — Sera Prognostics, The Pregnancy Company(™), announces that it has completed enrollment of 5,009 women into its prospective real-time study, “A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP).”
News

Intermountain Health and Christiana Care Health System Begin Enrollment on Two Landmark Preterm Birth Studies with PreTRM® Test

July 1, 2018 – Sera Prognostics®, The Pregnancy Company™, announces the recent launch of two new preterm birth studies using the PreTRM® test to identify high-risk mothers for intervention care.
News

Sera Prognostics Appoints Dr. Garrett K. Lam as Chief Medical Officer

Sera Prognostics, Inc., a women’s healthcare company, announced today that Garrett K. Lam, M.D., FACOG, will be joining the company as chief medical officer on September 4, 2018. Dr. Lam will direct all clinical development activities for Sera as the company achieves its vision to be The Pregnancy Company™. He will lead a group of talented clinical operations professionals who support Sera’s collaborations with research teams across the globe.
News

Sera Prognostics Collaborates with Christiana Care Health System to Launch New Preterm Birth Study with PreTRM® Test

June 19, 2018 — Sera Prognostics announced today that the first patient has been enrolled in the AVERT PRETERM TRIAL. This is the second intervention study to use Sera’s PreTRM® test to identify women at high risk of early delivery that will receive proactive interventions with the goal of reducing the rate of premature delivery and improving newborn health. The principal investigator for the study is Matthew Hoffman, M.D., MPH, FACOG, Marie E. Pinizzotto, M.D., Endowed Chair of Obstetrics and Gynecology at Christiana Care Health System in Wilmington, Delaware.
News

Intermountain Healthcare Launches New Study to Determine Benefit of Proactive Interventions in Reducing Premature Births

May 29, 2018 – Intermountain Healthcare announced it is launching the first study of its kind that will use Sera’s PreTRM® to identify those at risk for premature birth, and, in those with high risk, to evaluate the impact of early interventions designed to prolong their pregnancy and reduce the rate of premature delivery.
News

Key Strategies for Implementing Proteomics-Based Tests Across Disease States Highlighted in Current Opinion in Biotechnology

Seattle, WA and Salt Lake City, February 12 – Sera Prognostics, in collaboration with The Institute for Systems Biology and Integrated Diagnostics (Indi), today announced a paper entitled, “The building blocks of successful translation of proteomics to the clinic,” by Leroy Hood and colleagues published online in Current Opinion in Biotechnology.
News

Sera Prognostics to Present at the 11th Annual Canaccord Genuity Medical Technologies and Diagnostics Forum

SALT LAKE CITY, November 6, 2017–Sera Prognostics today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City. Dr. Critchfield’s presentation will take place at 2:30 PM E.T. on Thursday, November 9th, at the Westin Grand Central Hotel.
News

Sera Prognostics to Present at the Baird 2017 Global Healthcare Conference

SALT LAKE CITY, September 5, 2017 –Sera Prognostics today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Baird Global Healthcare Conference in New York City. Dr. Critchfield’s presentation will take place at 9:05 AM E.T. on Thursday, September 7th, at the InterContinental New York Barclay Hotel.

Stay in Touch